← Back to Screener
Tarsus Pharmaceuticals, Inc. Common Stock (TARS)
Price$67.72
Favorite Metrics
Price vs S&P 500 (26W)-1.05%
Price vs S&P 500 (4W)-0.61%
Market Capitalization$3.06B
All Metrics
Book Value / Share (Quarterly)$8.07
P/TBV (Annual)10.34x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)159.53%
Cash Flow / Share (Quarterly)$-0.52
Price vs S&P 500 (YTD)-14.95%
Gross Margin (TTM)93.20%
Net Profit Margin (TTM)-14.72%
EPS (TTM)$-1.61
10-Day Avg Trading Volume0.35M
EPS Excl Extra (TTM)$-1.61
EPS (Annual)$-1.59
ROI (Annual)-15.97%
Gross Margin (Annual)93.20%
Net Profit Margin (5Y Avg)-224.30%
Cash / Share (Quarterly)$9.81
Revenue Growth QoQ (YoY)128.39%
ROA (Last FY)-11.81%
Revenue Growth TTM (YoY)146.71%
EBITD / Share (TTM)$-1.68
ROE (5Y Avg)-36.06%
Operating Margin (TTM)-15.72%
Cash Flow / Share (Annual)$-0.52
P/B Ratio8.90x
P/B Ratio (Quarterly)10.12x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)6.52x
Net Interest Coverage (TTM)-7.94x
ROA (TTM)-12.70%
EPS Incl Extra (Annual)$-1.59
Current Ratio (Annual)3.85x
Quick Ratio (Quarterly)3.72x
3-Month Avg Trading Volume0.58M
52-Week Price Return47.37%
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$7.90
P/S Ratio (Annual)6.77x
Asset Turnover (Annual)0.80x
52-Week High$85.25
Operating Margin (5Y Avg)-233.48%
EPS Excl Extra (Annual)$-1.59
CapEx CAGR (5Y)84.59%
26-Week Price Return2.94%
Quick Ratio (Annual)3.72x
13-Week Price Return-4.94%
Total Debt / Equity (Annual)0.21x
Current Ratio (Quarterly)3.85x
Enterprise Value$2,944.425
Asset Turnover (TTM)0.86x
Book Value / Share Growth (5Y)-0.07%
Revenue / Employee (Annual)$1
Pretax Margin (Annual)-14.26%
Cash / Share (Annual)$9.81
3-Month Return Std Dev43.07%
Gross Margin (5Y Avg)93.94%
Net Income / Employee (TTM)$-0
ROE (Last FY)-19.34%
Net Interest Coverage (Annual)-26.58x
EPS Basic Excl Extra (Annual)$-1.59
P/FCF (TTM)104.22x
Receivables Turnover (TTM)6.85x
Total Debt / Equity (Quarterly)0.21x
EPS Incl Extra (TTM)$-1.61
Receivables Turnover (Annual)14.05x
ROI (TTM)-16.18%
P/S Ratio (TTM)6.77x
Pretax Margin (5Y Avg)-224.19%
Revenue / Share (Annual)$10.80
Tangible BV / Share (Annual)$7.90
Price vs S&P 500 (52W)17.54%
Year-to-Date Return-12.31%
5-Day Price Return-0.86%
EPS Normalized (Annual)$-1.59
ROA (5Y Avg)-25.72%
Net Profit Margin (Annual)-14.72%
Month-to-Date Return2.35%
Cash Flow / Share (TTM)$-3.86
EBITD / Share (Annual)$-1.68
Operating Margin (Annual)-15.72%
LT Debt / Equity (Annual)0.21x
ROI (5Y Avg)-30.49%
LT Debt / Equity (Quarterly)0.21x
EPS Basic Excl Extra (TTM)$-1.61
P/TBV (Quarterly)10.34x
P/B Ratio (Annual)10.12x
Inventory Turnover (TTM)8.78x
Pretax Margin (TTM)-14.26%
Book Value / Share (Annual)$8.07
Price vs S&P 500 (13W)-5.63%
Beta0.66x
P/FCF (Annual)966.97x
Revenue / Share (TTM)$10.55
ROE (TTM)-19.63%
52-Week Low$38.51
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.31
4.31
4.40
4.40
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
TARSTarsus Pharmaceuticals, Inc. Common Stock | 6.77x | 146.71% | 93.20% | — | $67.72 |
AMGNAmgen Inc | 5.13x | 9.95% | 73.30% | 2.93% | $349.39 |
GILDGilead Sciences Inc | 5.84x | 2.40% | 78.83% | 133.64% | $138.55 |
ARGXargenx SE American Depositary Shares | 12.46x | 89.56% | 150.91% | — | $828.35 |
BNTXBioNTech SE American Depositary Share | 8.75x | -11.81% | 84.21% | — | $102.12 |
BIIBBiogen Inc. Common Stock | 2.60x | 2.22% | 75.69% | -18.77% | $176.02 |
MRNAModerna, Inc. Common Stock | 11.02x | -39.93% | 70.32% | — | $54.68 |
NBIXNeurocrine Biosciences Inc | 4.49x | 21.45% | 98.18% | 2.31% | $128.41 |
EXELExelixis Inc | 4.96x | 6.85% | 96.39% | 31.10% | $44.38 |
TECHBio-Techne Corp. | 7.60x | 1.64% | 66.60% | -20.58% | $57.36 |
HALOHalozyme Therapeutics, Inc. | 5.74x | 37.55% | 83.62% | 22.89% | $66.64 |
About
Tarsus Pharmaceuticals is a commercial-stage biopharmaceutical company developing first-in-class therapeutics for eye care. Its lead product, XDEMVY, is an investigational eye drop for treating Demodex blepharitis, with additional candidates in development for ocular rosacea and other ophthalmic conditions.